Welcome to lbbc.org's website community for women living with metastatic breast cancer. We are dedicated to assisting you, and these pages offer easy access to a wealth of cutting-edge information specific to your needs.
In this community, you can read about the latest news on advanced disease, treatments and updates on clinical trials. Use the navigation bar on the left to quickly and easily access the topics of interest to you.
We hope the information and support offered in this section brings you comfort and enables you to make informed decisions regarding your physical and emotional health.
Every dollar you give helps LBBC continue to provide information and support at little to no cost.
- Research May Mean Fewer Side Effects For Women With Bone Metastases
- ASCO Issues First Guidelines for Metastatic HER2-positive Breast Cancer
- Everolimus Plus Exemestane — A Possible First-Line Therapy for Metastatic Disease
- Phase II Study Shows New Medicine May Slow Metastatic Breast Cancer
- Study Finds Higher Dose of Fulvestrant Reduces Risk of Death
Baltimore-based researchers seek participants with metastatic breast cancer for a phase II trial comparing a combination of chemotherapy plus a cancer vaccine with or without trastuzumab.
Postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that continued to grow during or after treatment with an aromatase inhibitor (anastrozole, letrozole, and exemestane) are needed for a clinical trial. Researchers conducting the trial are examining the safety and effectiveness of combining the PI3K inhibitor BMK120 with fulvestrant (Faslodex).
Living Beyond Breast Cancer expert Sara Tolaney, MD, answers your questions about making treatment decisions after a breast cancer diagnosis, from choosing the right care team to understanding your treatment options.